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Abstract
Background Poor diuretic response in acute heart failure
is related to poor clinical outcome. The underlying mech-
anisms and pathophysiology behind diuretic resistance are
incompletely understood. We evaluated a combined
approach using clinical characteristics and biomarkers to
predict diuretic response in acute heart failure (AHF).
Methods and results We investigated explanatory and
predictive models for diuretic response—weight loss at day
4 per 40 mg of furosemide—in 974 patients with AHF
included in the PROTECT trial. Biomarkers, addressing
multiple pathophysiological pathways, were determined at
baseline and after 24 h. An explanatory baseline biomarker
model of a poor diuretic response included low potassium,
chloride, hemoglobin, myeloperoxidase, and high blood
urea nitrogen, albumin, triglycerides, ST2 and neutrophil
gelatinase-associated lipocalin (r2 = 0.086). Diuretic
response after 24 h (early diuretic response) was a strong
predictor of diuretic response (b = 0.467, P\ 0.001;
r2 = 0.523). Addition of diuretic response after 24 h to
biomarkers and clinical characteristics significantly
improved the predictive model (r2 = 0.586, P\ 0.001).
Conclusions Biomarkers indicate that diuretic unrespon-
siveness is associated with an atherosclerotic profile with
abnormal renal function and electrolytes. However, predicting
diuretic response is difficult and biomarkers have limited
additive value. Patients at risk of poor diuretic response can be
identified by measuring early diuretic response after 24 h.
Keywords Diuretic response  Heart failure 
Biomarkers  Prediction
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MPO Myeloperoxidase
MR-proADM Mid regional pro-adrenomedullin
NGAL Neutrophil gelatinase-associated lipocalin
PROTECT Placebo-controlled randomized study of
the selective A1 adenosine receptor
antagonist rolofylline for patients
hospitalized with acute decompensated
heart failure and volume overload to
assess treatment effect on congestion and
renal function
RAGE Receptor for advanced glycation
endproducts
TNF-R1a Tumor necrosis factor receptor 1
Introduction
Treatment of acute heart failure (AHF) is primarily aimed
at decongestion using diuretics. Suboptimal response to
diuretics, or diuretic resistance, may reflect disease severity
and is associated with impaired renal function and poor
clinical outcome [1]. Recently, a definition for diuretic
response was introduced, combining weight loss and
diuretic dose, thus creating a quantitative indexed measure
of diuretic response [2, 3]. Patients with a poor diuretic
response had a significantly higher risk of post-discharge
death or heart failure rehospitalization. Identification of
patients with poor diuretic response or resistance early after
hospital admission might lead to adaptation of treatment,
potentially resulting in earlier relief of dyspnea, shorter
length of hospital stay and—hypothetically—a reduced
risk of hospital readmission early after discharge. Second,
the pathophysiology behind the individual variation in
diuretic response is not well understood. Valente et al.
previously published the association of a poor diuretic
response with more advanced heart failure, renal impair-
ment, diabetes, and atherosclerotic disease [2]. Biomarkers
might help in the early prediction of diuretic response
during hospital admission, and may provide additional
insights in the mechanisms underlying diuretic unrespon-
siveness. We, therefore, aimed to establish an explanatory
and predictive model for diuretic response in acute heart
failure using clinical characteristics and biomarkers from
different pathophysiological domains.
Methods
Study design and procedures
The study population and design has previously been
described in detail [4, 5]. In short, 2033 patients hospitalized
for acute heart failure with mild to moderate renal dysfunc-
tion participated in the placebo-controlled randomized study
of the selective A1 adenosine receptor antagonist rolofylline
for patients hospitalized with acute decompensated heart
failure and volume overload to assess treatment effect on
congestion and renal function (PROTECT). The PROTECT
study was a large, multicenter, phase III randomized clinical
trial with neutral results. The trial was approved by the local
ethics committee at each participating center. All patients
provided written informed consent.
At baseline and after 24 h, signs and symptoms of heart
failure were assessed, as well as standard laboratory
assessments. We selected 26 biomarkers based on their
known association with outcome or severity of heart failure,
renal function and atherosclerosis. Endothelial cell-selective
adhesion molecule (ESAM), growth differentiation factor 15
(GDF-15), lymphotoxin beta receptor (LTbR), mesothelin,
osteopontin, mid regional pro-adrenomedullin (MR-
proADM), receptor for advanced glycation endproducts
(RAGE), soluble ST2, syndecan-1, and tumor necrosis factor
alpha receptor 1 (TNF-R1a), were measured using sandwich
enzyme-linked immunosorbent assays (ELISAs) on a
Luminex platform by Alere Inc., San Diego, Ca, USA. By
use of competitive ELISAS on a Luminex platform
Angiogenin was measured. Finally, galectin-3, myeloper-
oxidase (MPO), and neutrophil gelatinase-associated lipo-
calin (NGAL) were measured using sandwich ELISAs on a
microtiter plate. Two additional biomarkers, brain natri-
uretic peptide (BNP), and Kidney Injury molecule (KIM-1),
were measured by single molecule counting technology by
Erenna Immunoassay System on a microtiter plate by
Singulex Inc., Alameda, CA, USA.
Definition of diuretic response and study population
Diuretic response was defined as weight change on day 4 per
40 mg of furosemide (or equivalent doses) administered
from baseline to day 3 as described earlier [2]. Early diuretic
response is defined as weight change after 24 h per 40 mg of
furosemide (or equivalent doses). Data on fluid intake, or
urine output was not available. Of the 2033 included patients,
1288 patients had complete biomarker data available at
baseline. A total of 1113 patients had additional complete
biomarker data after 24 h. Of these, 974 patients also had
data of diuretic response available. This study, therefore,
included a total study population of 974 patients. The
selected subpopulation did not significantly differ from the
excluded patients (supplementary Table 1).
Statistical analysis
The analyses were performed in the intention to treat
population. Continuous variables are presented as
146 Clin Res Cardiol (2016) 105:145–153
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mean ± standard deviation or median with (interquartile
range) when appropriate. Categorical values are presented
as frequencies and percentages. Differences between
groups were tested for significance with ANOVA (normal
distribution) and Kruskal–Wallis (skewed distribution). A
linear trend was statistically tested over quintiles of diuretic
response, after checking for non-linear trends.
Uni- and multivariable linear regression analysis was
performed with transformed values when necessary.
Transformations were checked using multifractional poly-
nomials. As a good diuretic response implicates lower
values, standardized beta’s need to be interpreted inverted,
where a negative standardized beta means higher values are
associated with a good diuretic response. Explanatory
models were created based on statistical significance,
whereas predictive models were selected on best fit [6].
Multivariable explanatory regression models, including all
univariable variables with a P value\0.10, were con-
structed via backward elimination and validated using
bootstrap re-sampling with 1000 replicates. The models
were tested for collinearity and checked by plotting resid-
uals. Finally, an internal bootstrap with 1000 replicates of
the selected models was performed, testing stability of
these models. Spearman’s rank correlation coefficient
(r) was used to assess the relation between predicted
diuretic response and diuretic response after 4 days.
A two tailed P value\0.05 was considered statistically
significant. Analyses were performed using R: a Language
and Environment for Statistical Computing, version 3.0.2.
(R Foundation for Statistical Computing, Vienna, Austria).
Results
Biomarkers at baseline per quintile of diuretic response are
presented in Table 1. Renal biomarkers, such as serum
creatinine, blood urea nitrogen (BUN), and plasma NGAL,
and atherosclerotic biomarkers (ESAM and LTbR) showed
significant trend over quintiles of diuretic response.
Potassium, chloride, and sodium were significantly lower
in patients with a poor response, whereas albumin and uric
acid were significantly higher.
A similar pattern was observed for biomarker levels
after 24 h (supplementary Table 2). Baseline characteris-
tics of this population per quintile of diuretic response are
presented in supplementary Table 3. In brief, poor
responders had a lower blood pressure, more frequent
diabetes and ischemic heart disease. An explanatory mul-
timarker biomarker model included albumin, BUN, chlo-
ride, hemoglobin, MPO, NGAL, potassium, ST2, and
triglycerides, but yielded only marginal explanatory value
of diuretic response (r2 = 0.086). Higher chloride, hemo-
globin, MPO and potassium levels were associated with a
good diuretic response (Table 2). In addition, a good
diuretic response was also associated with lower levels of
albumin, BUN, NGAL, ST2, and triglycerides.
In addition, an explanatory model for biomarkers after
24 h included BUN, hemoglobin, MPO, sodium, ST2, and
triglycerides (r2 = 0.082). Again, higher hemoglobin,
MPO, and sodium levels, and lower levels of BUN, ST2,
and triglycerides were associated with a good diuretic
response (supplementary Table 4). Finally, an explanatory
clinical baseline model (Table 3) showed that good diuretic
response was associated with higher systolic blood pres-
sure, higher weight and JVP, less frequent history of Dia-
betes Mellitus, PCI, COPD, beta blocker, and metolazone
use, and more spironolactone use and randomized rolo-
fylline treatment (r2 = 0.134).
Exploration of a model that contained variables 24 h
after randomization identified early diuretic response (after
24 h) as a strong predictor of good diuretic response
(univariable b = 0.467, P\ 0.001; r2 = 0.523) at 4 days.
In Fig. 1 median diuretic response and interquartile ranges
after 4 days are plotted per quintile of early diuretic
response from, respectively, good (quintile 1) to poor
response (quintile 5). This figure shows that a poor early
response had reasonable consistency with diuretic response
values after 4 days. Prediction of diuretic response at day 4
based on early diuretic response alone showed a strong
correlation (r = 0.723, P\ 0.001). The scatter plot of
predicted response (based on the early response after 24 h)
and measured diuretic response on day 4 is shown in
Fig. 2. Out of 974 patients, 98 patients (10.1 %) had a good
early diuretic response after 24 h ([median) and a poor
response on day 4 (Bmedian). Clinical characteristics and
biomarkers revealed no important differences between this
group and other groups based on response after 24 h and on
day 4.
Based on these findings, we explored a 24-h predictive
model for diuretic response (Table 4). In addition to early
diuretic response (after 24 h), BUN at baseline, change in
BUN (24 h—baseline), systolic blood pressure, weight at
baseline and randomized rolofylline treatment, as well as a
history of COPD, Diabetes Mellitus, PCI, and JVP were
included in the model. The use of spironolactone, and beta
blockers, baseline potassium, triglycerides, chloride, and
MPO, and ST2, and hemoglobin after 24 h further provided
a significant improvement of fit (r2 = 0.586, P\ 0.001).
Internal bootstrapping gave similar results.
Discussion
Poor response to diuretics in patients admitted with acute
heart failure is a clinical problem associated with high
morbidity and mortality. Using a panel of clinical and
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biochemical markers, we aimed to determine a non-re-
sponse profile for two reasons. First, it is of clinical rele-
vance to predict patients at risk, to initiate early alternative
therapies [7]. Second, a distinct clinical or biochemical
profile might provide more information about a patho-
physiological mechanism behind diuretic
unresponsiveness.
Identification of patients at risk of poor diuretic
response
Clinical characteristics and biomarkers fall short in pre-
dicting diuretic response. However, assessment of early
diuretic response after 24 h allows the clinician to identify
patients at risk of diuretic resistance shortly after hospital
admission. Although it is probably not surprising that
diuretic response at day 4 is predicted by early diuretic
response after only 24 h, it provides important clinical
application. This readily applicable metric can be used
daily in all patients hospitalized for acute heart failure.
Implementation of this metric in clinical practice will
identify both patients with favorable diuretic response and
patients with diuretic resistance early on during hospital-
ization. Once either of these patients are identified, treat-
ment strategies may be adapted. Alternative and sometimes
more aggressive strategies can be explored in patients with
significant unresponsiveness with a great risk of adverse
outcome, as these patients are more likely to benefit from
alternative therapies. Several strategies can be considered.
One of these is combination diuretic therapy—addition of a
thiazide diuretic or a mineralocorticoid receptor antagonist
at natriuretic doses—can help overcome diuretic resistance
and improve natriuresis [8–11]. Other alternatives are for
instance, adding dopamine or switching to ultrafiltration
[7]. Although the larger all-comer trials were neutral for
these therapies, both of these approaches have been
insufficiently investigated in truly unresponsive, diuretic
resistant patients. Our analyses also showed that random-
ized allocation to rolofylline, an adenosine A-1 antagonist,
was associated with a good diuretic response. This might
suggest that, in specific subpopulations, rolofylline may
help overcome poor diuretic response. Whether this will
Table 2 Explanatory
biomarker baseline model
Variable Beta coefficient 95 % CI T value P value
Albumin (per SD) 0.072 0.03 to 0.12 3.045 0.002
Log blood urea nitrogen (per SD) 0.076 0.02 to 0.13 2.797 0.005
Chloride (per SD) -0.066 -0.11 to -0.02 -2.772 0.006
Hemoglobin (per SD) -0.058 -0.11 to -0.01 -2.308 0.021
Myeloperoxidase (per SD) -0.060 -0.11 to -0.01 -2.490 0.013
NGAL (per SD) 0.064 0.01 to 0.12 2.307 0.021
Potassium (per SD) -0.103 -0.15 to -0.06 -4.333 \0.001
ST2 (per SD) 0.054 0.01 to 0.10 2.213 0.027
Triglycerides (per SD) 0.060 0.02 to 0.10 2.814 0.005
r2 = 0.086
NGAL neutrophil gelatinase-associated lipocalin
Table 3 Explanatory clinical
baseline model
Variable Beta coefficient 95 % CI T value P value
Weight (per SD) -0.089 -0.13 to -0.04 -3.781 \0.001
Systolic blood pressure (per SD) -0.082 -0.13 to -0.04 -3.648 \0.001
Rolofylline treatment -0.138 -0.23 to -0.05 -2.999 0.003
Jugular venous pressure -0.107 -0.19 to -0.02 -2.386 0.017
Diabetes mellitus 0.159 0.07 to 0.25 3.490 0.001
PCI 0.181 0.08 to 0.28 3.558 \0.001
COPD 0.127 0.02 to 0.23 2.294 0.022
Beta blocker 0.207 0.10 to 0.31 3.963 \0.001
Spironolactone -0.131 -0.22 to -0.04 -2.869 0.004
Metolazone 0.317 0.14 to 0.50 3.432 0.001
r2 = 0.134
PCI percutaneous coronary intervention, COPD chronic obstructive pulmonary disease
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Fig. 1 Diuretic response after 4 days per quintile of diuretic response after 24 h
Fig. 2 Scatter plot of predicted response and calculated diuretic response after 4 days
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also improve outcome is unknown. Future studies should
aim to investigate the effects of alternative strategies on
relieve of dyspnea and clinical outcome in patients
admitted for acute heart failure.
Predictors of diuretic response
Many clinical variables and biomarkers are related to
diuretic response. Our analyses show that a poor diuretic
response is strongly associated with renal and atherosclerotic
biomarkers, like creatinine, NGAL, ESAM and LTbR. The
clinical characteristics, previously described by Valente
et al. provided the same results in this smaller subset of
patients from the PROTECT cohort [2]. Atherosclerotic
characteristics as well as higher levels of novel atheroscle-
rotic biomarkers like ESAM and LTbR were associated with
a poor response. In the Dallas Heart study ESAM was
associated with subclinical atherosclerosis; while LTbR also
associated with multiple signs of atherosclerosis in this
study, confirming that a link between these markers and poor
diuretic response could be pointing towards a phenotype
with atherosclerotic properties [12, 13].
Interestingly, renal biomarkers, such as creatinine, BUN
and NGAL, were more abnormal over increasing quintiles of
diuretic response and were significant predictors of diuretic
response. Renal tubular function is of key importance for
diuretic efficacy [14]. The finding that higher levels of
plasma NGAL were associated with a poor diuretic response
supports this. However, as plasma KIM-1 was not signifi-
cantly associated with diuretic response; the question
remains whether circulating NGAL and KIM-1 levels both
reflect tubular function [15]. A higher creatinine and BUN
level was associated with a poor response to diuretic treat-
ment. Ferreira et al. previously identified plasma urea as a
predictor of slower diuretic response [16]. In our study, an
increase in BUN is also predictive of poor diuretic response,
suggesting not only baseline values but also worsening of
renal function is of influence on diuretic response. Both,
renin–angiotensin–aldosterone system and sympathetic
nervous system activation cause a flow-dependent passive
resorption of urea in the distal tubule, caused by increased
sodium and water resorption in the proximal tubule [17, 18].
This consequently results in diminished distal flow and
increased reabsorption. Elevated BUN levels, therefore,
indicate a kidney working actively to retain water and
sodium. This could be one of the reasons for the far greater
increase in BUN compared with serum creatinine with
poorer diuretic response. In addition, loop diuretics need to
be actively secreted by the organic anion transporter in the
proximal tubule to arrive at their site of action at the luminal
side of the tubule [19, 20]. Organic anions, like uric acid,
competitively bind this receptor, thus causing diminished
diuretic availability [21, 22].
Several electrolytes, like potassium, sodium and chlo-
ride showed associations with diuretic response. Interest-
ingly, higher chloride levels were associated with a better
Table 4 24 hour diuretic response prediction model
Variable Beta coefficient 95 % CI T value P value
Early diuretic response (after 24 h) (per SD) 0.479 0.45 to 0.51 28.052 \0.001
Systolic blood pressure (per SD) -0.068 -0.10 to -0.04 -4.208 \0.001
Change in blood urea nitrogen (24 h—baseline) (per SD) 0.055 0.02 to 0.09 3.403 0.001
Potassium at baseline (per SD) -0.053 -0.08 to -0.02 -3.207 0.001
COPD 0.111 0.03 to 0.19 2.869 0.004
Triglycerides at baseline (per SD) 0.038 0.01 to 0.07 2.646 0.008
Diabetes mellitus 0.079 0.01 to 0.14 2.397 0.017
Beta blocker 0.088 0.02 to 0.16 2.393 0.017
Weight (per SD) -0.037 -0.07 to -0.01 -2.279 0.023
Spironolactone -0.073 -0.14 to -0.01 -2.262 0.024
Jugular venous pressure -0.072 -0.13 to -0.01 -2.31 0.021
PCI 0.074 0.00 to 0.14 2.059 0.040
Log blood urea nitrogen at baseline (per SD) 0.033 0.00 to 0.07 1.920 0.055
Rolofylline treatment -0.060 -0.12 to 0.00 -1.883 0.060
ST2 after 24 h (per SD) 0.029 0.00 to 0.06 1.778 0.076
Hemoglobin after 24 h (per SD) -0.026 -0.06 to 0.01 -1.586 0.113
Chloride at baseline (per SD) -0.021 -0.05 to 0.01 -1.274 0.203
Myeloperoxidase at baseline (per SD) -0.019 -0.05 to 0.01 -1.152 0.250
r2 = 0.586
COPD chronic obstructive pulmonary disease, PCI percutaneous coronary intervention
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diuretic response. High chloride levels have been shown to
reduce renin release and increase blood pressure [23]. In
addition, loop diuretics inhibit the reabsorption of chloride
in the loop of Henle. A higher chloride level may, there-
fore, slightly suppress the renin-angiotensin-aldosterone
system, hence possibly increasing renal perfusion and
sodium reabsorption, and provide a less depleted chloride
level during diuretic treatment. Similarly, a low potassium
was associated with a poor diuretic response, likely due to
its co-transporter function.
Finally, MPO, ST2 and NGAL were the only ‘novel’
biomarkers in the multivariable models of diuretic
response. Interestingly, both ST2 and MPO are thought to
be associated with a pro-inflammatory state. Higher MPO
levels are associated with more advanced heart failure and
adverse outcome in chronic heart failure patients [24]. In
patients with acute coronary syndrome, pre-admission
treatment with statins, beta blockers or ACE inhibitors
reduced MPO levels [25]. In this study we paradoxically
found an association between low MPO levels and poor
diuretic response. Higher ST2 levels have been found in
chronic kidney disease patients and correlated with disease
severity [26]. Addition of ST2 to BNP in acute heart failure
patients has been shown to improve prognostic accuracy
[27].
Limitations
This study is a retrospective analysis of a randomized clinical
trial. Unfortunately, not all patients had complete biomarker
data available at baseline and after 24 h, creating a selected
subpopulation used for these analyses. In addition, these
analyses are data driven and causality cannot be proven. The
results of this study need to be validated in a different pop-
ulation. Research assays to MR-proADM, galectin-3, and
ST2 were developed by Alere, and have not been standard-
ized to the commercialized assays used in research or in
clinical use. The extent to which each Alere assay correlates
with the commercial assay is not fully characterized. Infor-
mation on fluid intake, urine output or net fluid balance was
not collected in the PROTECT database. We were unfortu-
nately not able to compare diuretic response based on weight
loss to other metrics, for instance based on urine excretion or
net fluid loss.
Conclusions
Biomarkers indicate that poor diuretic response is associ-
ated with a profile of atherosclerosis, glomerular and
tubular renal dysfunction and abnormal electrolytes. These
markers were of limited clinical use to predict diuretic
response at hospital admission for acute heart failure.
Patients at risk of diuretic resistance can be identified by
measuring diuretic response after 24 h.
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